| pubmed-article:18791271 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18791271 | lifeskim:mentions | umls-concept:C0215848 | lld:lifeskim |
| pubmed-article:18791271 | lifeskim:mentions | umls-concept:C2348977 | lld:lifeskim |
| pubmed-article:18791271 | lifeskim:mentions | umls-concept:C1822686 | lld:lifeskim |
| pubmed-article:18791271 | lifeskim:mentions | umls-concept:C2348110 | lld:lifeskim |
| pubmed-article:18791271 | lifeskim:mentions | umls-concept:C1701901 | lld:lifeskim |
| pubmed-article:18791271 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:18791271 | pubmed:dateCreated | 2008-9-15 | lld:pubmed |
| pubmed-article:18791271 | pubmed:abstractText | Hypoxia is a hallmark of solid cancers and triggers the transcription of genes responsible for cell survival. The transcription factor Hypoxia-Inducible Factor 1 (HIF-1) is a key regulator in this response and frequently activated in human cancer. HIF-1 activation is associated with tumor aggressiveness and poor clinical outcome and, therefore, may provide an attractive therapeutic target. Here we provide a novel approach for HIF-1 targeted therapy using single-domain llama antibodies directed against the HIF-1alpha oxygen dependent degradation domain which encompass the N-terminal transactivation domain. Conditional expression of HIF intrabodies in mammalian cells interfered with binding to pVHL and inhibited hypoxia induced activation of endogenous target genes. Inducible intrabody targeting is a highly specific strategy for temporal protein inactivation and may have applications for disease treatment. | lld:pubmed |
| pubmed-article:18791271 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18791271 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18791271 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18791271 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18791271 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18791271 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18791271 | pubmed:issn | 1570-5870 | lld:pubmed |
| pubmed-article:18791271 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:18791271 | pubmed:author | pubmed-author:VooijsMarcM | lld:pubmed |
| pubmed-article:18791271 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:18791271 | pubmed:author | pubmed-author:GrootArjan... | lld:pubmed |
| pubmed-article:18791271 | pubmed:author | pubmed-author:GortEelke HEH | lld:pubmed |
| pubmed-article:18791271 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18791271 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:18791271 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18791271 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18791271 | pubmed:pagination | 397-409 | lld:pubmed |
| pubmed-article:18791271 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:meshHeading | pubmed-meshheading:18791271... | lld:pubmed |
| pubmed-article:18791271 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18791271 | pubmed:articleTitle | Conditional inactivation of HIF-1 using intrabodies. | lld:pubmed |
| pubmed-article:18791271 | pubmed:affiliation | Department of Pathology, University Medical Center Utrecht, 3508 GA, Utrecht, The Netherlands. | lld:pubmed |
| pubmed-article:18791271 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18791271 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18791271 | lld:pubmed |
